Osteogenic Composition Coloring Agent Bone Growth Leakage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bone grafting procedures often face challenges with excessive growth factor leakage, leading to a destabilized microenvironment and reduced efficacy in promoting bone growth, as surgeons struggle to visualize and control the distribution of growth factors during matrix application.
Innovation Solution
An osteogenic composition is developed that includes a growth factor, a coloring agent, and a biodegradable porous collagen matrix, where the coloring agent imparts a visible color to the growth factor, allowing surgeons to monitor its distribution and prevent excessive leakage, thereby maintaining the matrix's efficacy over time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If growth factor is applied to promote bone growth, then bone formation is enhanced, but excessive leakage occurs causing microenvironment destabilization and reduced efficacy
Solution Approach 1:
The patent applies color changes by incorporating a coloring agent into the growth factor composition. This allows the growth factor to be visually tracked during application and release, enabling surgeons to monitor distribution and detect excessive leakage. The color change principle transforms an invisible biochemical process into a visible indicator system that provides real-time feedback on growth factor behavior.
Solution Approach 2:
The patent implements feedback by using the colored growth factor composition as a visual monitoring system. The color provides immediate feedback to the surgeon about where the growth factor is located and how it is distributing, allowing real-time adjustment of the application process to prevent excessive leakage and maintain optimal concentrations at the target site.
2Stability of the object's composition
If growth factor distribution is monitored to prevent leakage, then microenvironment stability is improved, but visualization capability is initially insufficient
Solution Approach 1:
The patent directly addresses the visualization difficulty by incorporating a coloring agent that imparts visible color to the growth factor composition. This transforms the invisible growth factor into a visually detectable substance, allowing surgeons to easily monitor its distribution, concentration, and leakage in real-time during the procedure without requiring complex imaging equipment.
3Difficulty of detecting and measuring
If coloring agent is added to growth factor, then visualization of distribution is improved, but composition complexity increases
Solution Approach 1:
The patent applies color changes by incorporating a coloring agent into the growth factor composition. This allows the growth factor to be visually tracked during application and release, enabling surgeons to monitor distribution and detect excessive leakage. The color change principle transforms an invisible biochemical process into a visible indicator system that provides real-time feedback on growth factor behavior.
Solution Approach 2:
The coloring agent serves as an intermediary substance that does not directly participate in the bone growth process but facilitates visualization and monitoring. This intermediary enables the surgeon to track the growth factor without interfering with its biological function, providing a passive optical indicator that simplifies monitoring while maintaining the primary therapeutic mechanism.
Data Source
AI summary
An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein-2 and a coloring agent to form a mixture; applying the mixture to a surface of a porous collagen matrix, wherein the coloring agent allows the user to see bone morphogenic protein-2 distribution on or in the porous collagen matrix; and implanting the porous collagen matrix at or near a target tissue site in need of bone repair.